Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # FDA July 2026 Peptide Meeting: What Patients Need to Know About Access, Approval, and Safety Meto blog Influencers are Lying About the FDA and Peptides This is the Truth (May 2026) FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of